Clinical Trial Update: A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens [Phase 1]

View source ↗

Summary

This report summarizes a two-stage Phase 1 dose-escalation pharmacokinetic study of Tarceva (erlotinib) in smokers with stage IIIB/IV non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: OSI Pharmaceuticals | Conditions: NSCLC | Phase 1 | Status: COMPLETED